Adventus Partners supports biotechnology and pharmaceutical companies of all sizes and stages of development, including start-ups, development-stage, and established commercial companies.
We believe in building lasting relationships that enable us to execute quickly and efficiently when client needs arise.
Representative Clients
(now Invivyd)
(NASDAQ: IVVD)
(NASDAQ: ALNY)
(NASDAQ: APGE)
(ASX: ALA)
(NASDAQ: BLUE)
(acquired by Organon Pharma)
(merged with Korro Bio)
(NASDAQ: KRRO)
(acquired by Astellas)
(NASDAQ: ISEE)
(merged with Dianthus Therapeutics)
(NASDAQ: MGTA)
(NASDAQ Copenhagen: ORPHA)
(NASDAQ: SYBX)
(acquired by Sanofi)
(now Repertoire Immune Medicines)
(NASDAQ: TCRX)
(NASDAQ: VSTM)
(NASDAQ: VYGR)
(now WaveBreak)